# Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile
Canonical URL: https://biopharmsignal.com/news/ARTL/artelo-announces-peer-reviewed-publication-supporting-its-fabp5-inhibitor-art26-12-as-a-novel-pain-treatment-with-a-potentially-first-in-class-profile
Ticker: ARTL
Company: Artelo Biosciences
Source: Artelo Biosciences
Published: 2026-04-20 11:50 EST
Original Source URL: https://ir.artelobio.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-22 12:39 EST — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432) — Source: Artelo Biosciences
- 2026-07-16 12:48 EST — [Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions](https://biopharmsignal.com/news/ARTL/artelo-biosciences-announces-results-from-a-nonclinical-osteoarthritis-study-sup-fa16911f) — Source: Artelo Biosciences
- 2026-07-14 12:47 EST — [Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026](https://biopharmsignal.com/news/ARTL/artelo-biosciences-issues-reminder-to-shareholders-to-vote-in-advance-of-annual--371c2cf4) — Source: Artelo Biosciences
- 2026-07-13 13:02 EST — [Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy](https://biopharmsignal.com/news/ARTL/artelo-biosciences-announces-positive-results-with-art27-13-in-a-nonclinical-mod-86480dfe) — Source: Artelo Biosciences
- 2026-07-01 12:42 EST — [Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury](https://biopharmsignal.com/news/ARTL/artelo-biosciences-announces-new-data-supporting-art26-12-as-a-potential-first-i-d595235b) — Source: Artelo Biosciences
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)